Adipose‑derived mesenchymal stem cell‑facilitated TRAIL expression in melanoma treatment in vitro

Jing,Hai Xia; Duan,De Jian; Zhou,Hui; Hu,Qing Mei; Lei,Tie Chi

doi:10.3892/mmr.2016.5283

Adipose‑derived mesenchymal stem cell‑facilitated TRAIL expression in melanoma treatment in vitro

Authors:
- Hai Xia Jing
- De Jian Duan
- Hui Zhou
- Qing Mei Hu
- Tie Chi Lei
View Affiliations

Affiliations: Department of Dermatology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Dermatology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: May 13, 2016 https://doi.org/10.3892/mmr.2016.5283
Pages: 195-201
Copyright: © Jing et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adipose-derived stem cells (ADSCs) may be useful as an efficient vehicle in cell-based gene therapy of human diseases due to their ability to migrate to disease lesions. This study investigated the ability of ADSC‑harbored human tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) cDNA to facilitate TRAIL expression and induce A375 melanoma cell apoptosis as observed using a Transwell co‑culture system. A cell migration assay was used to observe ADSC migration ability. In addition, TRAIL protein expression was successfully detected by western blot analysis in ADSCs after stable transfection of TRAIL cDNA. The Transwell co‑culture system data showed that TRAIL-ADSCs could induce A375 cell apoptosis in a dose‑dependent manner. At the gene level, the killing activity of TRAIL-ADSCs was associated with activation of caspase‑4 and caspase‑8. Collectively, the data from the current study provides preclinical support of ADSC‑facilitated TRAIL expression in the treatment of melanoma. Further investigation is required to evaluate and confirm the in vivo ability of TRAIL-ADSCs in therapy of melanoma in animal models.

View Figures

View References

1	Vandamme N and Berx G: Melanoma cells revive an embryonic transcriptional network to dictate phenotypic heterogeneity. Front Oncol. 4:3522014. View Article : Google Scholar : PubMed/NCBI
2	Stewart BW and Wild CP: World Health Organization World Cancer Report 2014. Chapter5.14; pp. 495–502. 2014
3	Jerant AF, Johnson JT, Sheridan CD and Caffrey TJ: Early detection and treatment of skin cancer. Am Fam Physician. 62:357–368. 375–376. 381–382. 2000.PubMed/NCBI
4	Halachmi S and Gilchrest BA: Update on genetic events in the pathogenesis of melanoma. Cur Opin Oncol. 13:129–136. 2001. View Article : Google Scholar
5	Kanavy HE and Gerstenblith MR: Ultraviolet radiation and melanoma. Semin Cutan Med Surg. 30:222–228. 2011. View Article : Google Scholar : PubMed/NCBI
6	Jost LM; ESMO Guidelines Task Force: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma. Ann Oncol. 14:1012–1013. 2003. View Article : Google Scholar : PubMed/NCBI
7	Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American joint committee on cancer melanoma staging system. J Clin Oncol. 19:3622–3634. 2001.PubMed/NCBI
8	Sun XY, Nong J, Qin K, Lu H, Moniri MR, Dai LJ and Warnock GL: MSC(TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures. Anticancer Res. 31:3705–3712. 2011.PubMed/NCBI
9	Loebinger MR and Janes SM: Stem cells as vectors for anti-tumour therapy. Thorax. 65:362–369. 2010. View Article : Google Scholar : PubMed/NCBI
10	Dai LJ, Moniri MR, Zeng ZR, Zhou JX, Rayat J and Warnock GL: Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett. 305:8–20. 2011. View Article : Google Scholar : PubMed/NCBI
11	Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L and Zhu J: Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Neurosurgery. 65:610–624. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ivanov DP, Parker TL, Walker DA, Alexander C, Ashford MB, Gellert PR and Garnett MC: In vitro co-culture model of medulloblastoma and human neural stem cells for drug delivery assessment. J Biotechnol. 205:3–13. 2015. View Article : Google Scholar : PubMed/NCBI
13	Mao ZG, Jiang CC, Yang F, Thorne RF, Hersey P and Zhang XD: TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4. Apoptosis. 15:1211–1222. 2010. View Article : Google Scholar : PubMed/NCBI
14	Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luriá EA and Ruadkow IA: Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 2:83–92. 1974.PubMed/NCBI
15	Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP and Hedrick MH: Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng. 7:211–228. 2001. View Article : Google Scholar : PubMed/NCBI
16	Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P and Hedrick MH: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 13:4279–4295. 2002. View Article : Google Scholar : PubMed/NCBI
17	Kern S, Eichler H, Stoeve J, Klüter H and Bieback K: Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 24:1294–1301. 2006. View Article : Google Scholar : PubMed/NCBI
18	Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI
19	Wu GS: TRAIL as a target in anti-cancer therapy. Cancer Lett. 285:1–5. 2009. View Article : Google Scholar : PubMed/NCBI
20	Rosenecker J, Huth S and Rudolph C: Gene therapy for cystic fibrosis lung disease: Current status and future perspectives. Curr Opin Mol Ther. 8:439–445. 2006.PubMed/NCBI
21	Yamashita Y, Shimada M, Tanaka S, Okamamoto M, Miyazaki J and Sugimachi K: Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma. Hum Gene Ther. 13:275–286. 2002. View Article : Google Scholar : PubMed/NCBI
22	Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
23	Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, et al: Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 70:3718–3729. 2010. View Article : Google Scholar : PubMed/NCBI
24	Dy GK and Adjei AA: Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 63:249–279. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zangi L, Lui KO, von Gise A, Ma Q, Ebina W, Ptaszek LM, Später D, Xu H, Tabebordbar M, Gorbatov R, et al: Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 31:898–907. 2013. View Article : Google Scholar : PubMed/NCBI
26	Yoshioka N, Gros E, Li HR, Kumar S, Deacon DC, Maron C, Muotri AR, Chi NC, Fu XD, Yu BD and Dowdy SF: Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell. 13:246–254. 2013. View Article : Google Scholar : PubMed/NCBI
27	Leonhardt C, Schwake G, Stögbauer TR, Rappl S, Kuhr JT, Ligon TS and Rädler JO: Single-cell mRNA transfection studies: Delivery, kinetics and statistics by numbers. Nanomedicine. 10:679–688. 2014.
28	Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E and Rhoads RE: Synthesis and properties of mRNAs containing the novel 'anti-reverse' cap analogs 7-methyl (3′-O-methyl) GpppG and 7-methyl (3′-deoxy) GpppG. RNA. 7:1486–1495. 2001.PubMed/NCBI